Therapeutic angiogenesis: A comparative study of the angiogenic potential of acidic fibroblast growth factor and heparin Todd K. Rosengart, MD, Kurt.

Slides:

Advertisements

Similar presentations

Endothelial cell seeding reduces thrombogenicity of Dacron grafts in humans Per Örtenwall, MD, PhD *, Hans Wadenvik, MD, PhD **, Jack Kutti, MD, PhD **,

Advertisements

The role of arteriovenous shunts in the pathogenesis of varicose veins Howard C. Baron, M.D., Sebastiano Cassaro, M.D. Journal of Vascular Surgery Volume.

The effect of inguinal lymphatic manipulation on regional lymph flow patterns Jeffrey R. Rubin, MD, Lisa B. Eberlin, MD Journal of Vascular Surgery Volume.

Ultrasound-guided percutaneous delivery of tissue-engineered endothelial cells to the adventitia of stented arteries controls the response to vascular.

Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower.

Clinical evaluation of recombinant human platelet – derived growth factor for the treatment of lower extremity diabetic ulcers David L. Steed, MD, the.

Heparin-coated catheters and heparin-induced thrombocytopenia

Uswa Shahzad, BHSc, Guangming Li, MD, Yaoguang Zhang, MD, Terrence M

Therapeutic angiogenesis: A comparative study of the angiogenic potential of acidic fibroblast growth factor and heparin Todd K. Rosengart, MD, Kurt.

Axillary-to-carotid artery bypass grafting for symptomatic severe common carotid artery occlusive disease Joseph P. Archie, PhD, MD Journal of Vascular.

Expression of molecular mediators of apoptosis and their role in the pathogenesis of lower-extremity varicose veins Enrico Ascher, MD, Theresa Jacob,

Recovery from hind limb ischemia is less effective in type 2 than in type 1 diabetic mice: Roles of endothelial nitric oxide synthase and endothelial.

Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model Abdulaziz Al-Khaldi, MD, Hilal.

Robert J. Pitsch, MD, David J. Minion, MD, Margaret L

Neovasculogenic Therapy to Augment Perfusion and Preserve Viability in Ischemic Cardiomyopathy Pavan Atluri, MD, George P. Liao, MB, Corinna M. Panlilio,

Gastroesophageal tumor embolization to the popliteal arteries

Combination of stromal-derived factor-1α and vascular endothelial growth factor gene- modified endothelial progenitor cells is more effective for ischemic.

Karen M. Newman, PhD, Jessie Jean-Claude, MD, Hong Li, MS, John V

Thomas E. Arnold, MD, Dmitri Gnatenko, PhD, Wadie F. Bahou, MD

Nicholas P. Ziats, PhD, James M. Anderson, MD, PhD

Photodynamic therapy inactivates extracellular matrix–basic fibroblast growth factor: Insights to its effect on the vascular wall Glenn M. LaMuraglia,

Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit.

Alex Westerband, MD, Joseph L. Mills, MD, John M. Marek, MD, Ronald L

Mark F. Fillinger, MD, Susan E. O'Connor, MD, Robert J

The neuroprotective effects of intrathecal administration of the selective N-type calcium channel blocker ziconotide in a rat model of spinal ischemia

Mechanisms of arterial graft failure. II

Michael A. Golden, MD, Y. P. Tina Au, PhD, Richard D

Malcolm O. Perry, MD, Richard Kempczinski, MD

Ultrasound-guided percutaneous delivery of tissue-engineered endothelial cells to the adventitia of stented arteries controls the response to vascular.

Antisense basic fibroblast growth factor gene transfer reduces early intimal thickening in a rabbit femoral artery balloon injury model David G. Neschis,

Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion

Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury Abigail K. Hanna, MD, Jonathan C. Fox, MD,

Heparin-coated catheters and heparin-induced thrombocytopenia

Delayed inhaled carbon monoxide mediates the regression of established neointimal lesions Michael Madigan, MD, Fateh Entabi, MD, Brian Zuckerbraun, MD,

Recovery from hind limb ischemia is less effective in type 2 than in type 1 diabetic mice: Roles of endothelial nitric oxide synthase and endothelial.

Increased ICAM-1 expression in aortic disease

Todd K. Rosengart, M. D. , John P. Kupferschmid, M. D. , Victor J

Thrombolysis for experimental deep venous thrombosis maintains valvular competence and vasoreactivity Jeffrey M. Rhodes, MD, Jae-Sung Cho, MD, Peter.

John Blebea, MD, Robert A. Cambria, MD, David DeFouw, PhD, Richard N

Angiogenic pretreatment to enhance myocardial function after cellular cardiomyoplasty with skeletal myoblasts Mauricio A. Retuerto, BS, James T. Beckmann,

Objective tinnitus resulting from internal carotid artery stenosis

Primary leiomyosarcoma of the abdominal aorta

Hemodynamic unloading leads to regression of pulmonary vascular disease in rats Stacy B. O'Blenes, MD, MSca, Stefan Fischer, MDb, Brendan McIntyre, BSca,

Julia Humphries, MSc, Catharine L

Controlled delivery of vascular endothelial growth factor promotes neovascularization and maintains limb function in a rabbit model of ischemia Steven.

The effect of carbon coating and porosity on early patency of expanded polytetrafluoroethylene grafts: An experimental study Donald L. Akers, MD, Yong.

Development of a spontaneously beating vein by cardiomyocyte transplantation in the wall of the inferior vena cava in a rat: A pilot study Wangde Dai,

Immunosuppressive treatment of aortic allografts

The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms David A. Bigatel, MD, James R. Elmore, MD, David.

Calvin B. Ernst, MD Journal of Vascular Surgery

Changes in the cooling rate and medium improve the vascular function in cryopreserved porcine femoral arteries Montserrat Rigol, PhD, Magda Heras, MD,

Complement activation by synthetic vascular prostheses

Cardiovascular surgery—The rocket and its stars: Presidential address

Heparin-associated thrombocytopenia and thrombosis: A serious clinical problem and potential solution Raymond G. Makhoul, M.D., Charles S. Greenberg,

Research and research funding in vascular surgery

J.Dennis Baker, MD Journal of Vascular Surgery

Gary W. Barone, MD, Axel W. Joob, MD, Terry L. Flanagan, MPH, Carey E

Recovery from hind limb ischemia is less effective in type 2 than in type 1 diabetic mice: Roles of endothelial nitric oxide synthase and endothelial.

Phillip J. Cozzi, B. S. , Ross T. Lyon, M. D. , Harry R. Davis, Ph. D

Seizures following subclavian-carotid bypass

Richard J. Sanders, MD 1, William H. Pearce, MD 2

Monitoring vascular surgical performance

D. Emerick Szilagyi, MD—An appreciation

Presidential address: The second-generation vascular surgeon

George D. Lilly 1906–1988 Journal of Vascular Surgery

James A. DeWeese, MD Journal of Vascular Surgery

Axillary-to-carotid artery bypass grafting for symptomatic severe common carotid artery occlusive disease Joseph P. Archie, PhD, MD Journal of Vascular.

Thigh claudication due to profunda femoris artery occlusion

Prevention of stenosis after vascular reconstruction: Pharmacologic control of intimal hyperplasia—A review Alexander W. Clowes, MD, Michael A. Reidy,

Endovascular repair of two abdominal aortic aneurysms

Presentation transcript:

Therapeutic angiogenesis: A comparative study of the angiogenic potential of acidic fibroblast growth factor and heparin Todd K. Rosengart, MD, Kurt T. Budenbender, BS, Martin Duenas, BS, Charles A. Mack, MD, Qing-Xue Zhang, PhD, O.Wayne Isom, MD Journal of Vascular Surgery Volume 26, Issue 2, Pages 302-312 (August 1997) DOI: 10.1016/S0741-5214(97)70193-9 Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 1 Percent PCNA labeling per total cell nuclei. Biopsies were taken of fibrofatty tissues distal to the point of vascular ligation 10 days after vascular ligation, after daily administration of one of the following: 1 ml saline solution (n = 13); 0.05 mg heparin in 1 ml saline solution (n = 13); 1 μg aFGF (n = 5); or 1 μg recombinant human aFGF and 0.05 mg heparin in 1 ml saline solution (n = 5). Histogram depicts PCNA labeling as percentage of total cell nuclei that is increased in heparin-treated group, and is increased to a greater extent in aFGF and aFGF/heparin groups, compared with saline solution controls. Error bars represent SEM. Journal of Vascular Surgery 1997 26, 302-312DOI: (10.1016/S0741-5214(97)70193-9) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 2 Photomicrographs (original magnification, 400×) of PCNA immunohistochemical preparations after various treatment regimens. Biopsies of fibrofatty tissue distal to the point of vascular ligation were obtained 10 days after vascular occlusion in animals treated with daily administration of one of the following: 1 ml saline solution (n = 13); 0.05 mg heparin in 1 ml saline solution (n = 13); 1 μg aFGF (n = 5); or 1 μg recombinant human aFGF and 0.05 mg heparin in 1 ml saline solution (n = 5). Saline solution controls (A) demonstrate predominant methyl green counterstain (blue appearance) and almost no brown PCNA labeling. PCNA labeling is increased in heparin-treated rats (B) and is increased to a greater extent in aFGF-treated animals (C) and aFGF/heparin-treated animals (D). Red blood cells are visible within vasculature (arrows) that is delineated by PCNA labeling. Labeling of vascular endothelial cells (arrows) is visible in aFGF/heparin-treated tissues (E) viewed at higher magnification (original magnification, 1000×). Journal of Vascular Surgery 1997 26, 302-312DOI: (10.1016/S0741-5214(97)70193-9) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 2 Photomicrographs (original magnification, 400×) of PCNA immunohistochemical preparations after various treatment regimens. Biopsies of fibrofatty tissue distal to the point of vascular ligation were obtained 10 days after vascular occlusion in animals treated with daily administration of one of the following: 1 ml saline solution (n = 13); 0.05 mg heparin in 1 ml saline solution (n = 13); 1 μg aFGF (n = 5); or 1 μg recombinant human aFGF and 0.05 mg heparin in 1 ml saline solution (n = 5). Saline solution controls (A) demonstrate predominant methyl green counterstain (blue appearance) and almost no brown PCNA labeling. PCNA labeling is increased in heparin-treated rats (B) and is increased to a greater extent in aFGF-treated animals (C) and aFGF/heparin-treated animals (D). Red blood cells are visible within vasculature (arrows) that is delineated by PCNA labeling. Labeling of vascular endothelial cells (arrows) is visible in aFGF/heparin-treated tissues (E) viewed at higher magnification (original magnification, 1000×). Journal of Vascular Surgery 1997 26, 302-312DOI: (10.1016/S0741-5214(97)70193-9) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 2 Photomicrographs (original magnification, 400×) of PCNA immunohistochemical preparations after various treatment regimens. Biopsies of fibrofatty tissue distal to the point of vascular ligation were obtained 10 days after vascular occlusion in animals treated with daily administration of one of the following: 1 ml saline solution (n = 13); 0.05 mg heparin in 1 ml saline solution (n = 13); 1 μg aFGF (n = 5); or 1 μg recombinant human aFGF and 0.05 mg heparin in 1 ml saline solution (n = 5). Saline solution controls (A) demonstrate predominant methyl green counterstain (blue appearance) and almost no brown PCNA labeling. PCNA labeling is increased in heparin-treated rats (B) and is increased to a greater extent in aFGF-treated animals (C) and aFGF/heparin-treated animals (D). Red blood cells are visible within vasculature (arrows) that is delineated by PCNA labeling. Labeling of vascular endothelial cells (arrows) is visible in aFGF/heparin-treated tissues (E) viewed at higher magnification (original magnification, 1000×). Journal of Vascular Surgery 1997 26, 302-312DOI: (10.1016/S0741-5214(97)70193-9) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 2 Photomicrographs (original magnification, 400×) of PCNA immunohistochemical preparations after various treatment regimens. Biopsies of fibrofatty tissue distal to the point of vascular ligation were obtained 10 days after vascular occlusion in animals treated with daily administration of one of the following: 1 ml saline solution (n = 13); 0.05 mg heparin in 1 ml saline solution (n = 13); 1 μg aFGF (n = 5); or 1 μg recombinant human aFGF and 0.05 mg heparin in 1 ml saline solution (n = 5). Saline solution controls (A) demonstrate predominant methyl green counterstain (blue appearance) and almost no brown PCNA labeling. PCNA labeling is increased in heparin-treated rats (B) and is increased to a greater extent in aFGF-treated animals (C) and aFGF/heparin-treated animals (D). Red blood cells are visible within vasculature (arrows) that is delineated by PCNA labeling. Labeling of vascular endothelial cells (arrows) is visible in aFGF/heparin-treated tissues (E) viewed at higher magnification (original magnification, 1000×). Journal of Vascular Surgery 1997 26, 302-312DOI: (10.1016/S0741-5214(97)70193-9) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 2 Photomicrographs (original magnification, 400×) of PCNA immunohistochemical preparations after various treatment regimens. Biopsies of fibrofatty tissue distal to the point of vascular ligation were obtained 10 days after vascular occlusion in animals treated with daily administration of one of the following: 1 ml saline solution (n = 13); 0.05 mg heparin in 1 ml saline solution (n = 13); 1 μg aFGF (n = 5); or 1 μg recombinant human aFGF and 0.05 mg heparin in 1 ml saline solution (n = 5). Saline solution controls (A) demonstrate predominant methyl green counterstain (blue appearance) and almost no brown PCNA labeling. PCNA labeling is increased in heparin-treated rats (B) and is increased to a greater extent in aFGF-treated animals (C) and aFGF/heparin-treated animals (D). Red blood cells are visible within vasculature (arrows) that is delineated by PCNA labeling. Labeling of vascular endothelial cells (arrows) is visible in aFGF/heparin-treated tissues (E) viewed at higher magnification (original magnification, 1000×). Journal of Vascular Surgery 1997 26, 302-312DOI: (10.1016/S0741-5214(97)70193-9) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 3 Percent PCNA labeling per vascular cell nuclei. Biopsies were taken of fibrofatty tissues distal to the point of vascular ligation 10 days after vascular ligation, after the daily administration of one of the following: 1 ml saline solution (n = 13); 0.05 mg heparin in 1 ml saline solution (n = 13); 1 μg aFGF (n = 5); or 1 μg recombinant human aFGF and 0.05 mg heparin in 1 ml saline solution (n = 5). Histogram depicts PCNA labeling as percentage of vascular cell nuclei that is increased in heparin-treated group, and is increased to a greater extent in aFGF and aFGF/heparin groups, compared with saline solution controls. Error bars represent SEM. Journal of Vascular Surgery 1997 26, 302-312DOI: (10.1016/S0741-5214(97)70193-9) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 4 Vascular density (fibrofatty tissue). Biopsies of fibrofatty tissues distal to the point of vascular ligation were obtained 10 days after vascular occlusion in animals treated with daily administration of one of the following: 1 ml saline solution (n = 13); 0.05 mg heparin in 1 ml saline solution (n = 13); 1 μg aFGF (n = 5); or 1 μg recombinant human aFGF and 0.05 mg heparin in 1 ml saline solution (n = 5). Vessel number was determined per low power field (100×) as described in Methods section. Representative low power fields are depicted for (A) saline solution group and (B) aFGF/heparin-treated animals. C, Histogram depicts vessel number per microscopic field that is increased in heparin-treated group, and is increased to a greater extent in the aFGF and aFGF/heparin groups, compared with saline solution controls. Error bars represent SEM. Journal of Vascular Surgery 1997 26, 302-312DOI: (10.1016/S0741-5214(97)70193-9) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 4 Vascular density (fibrofatty tissue). Biopsies of fibrofatty tissues distal to the point of vascular ligation were obtained 10 days after vascular occlusion in animals treated with daily administration of one of the following: 1 ml saline solution (n = 13); 0.05 mg heparin in 1 ml saline solution (n = 13); 1 μg aFGF (n = 5); or 1 μg recombinant human aFGF and 0.05 mg heparin in 1 ml saline solution (n = 5). Vessel number was determined per low power field (100×) as described in Methods section. Representative low power fields are depicted for (A) saline solution group and (B) aFGF/heparin-treated animals. C, Histogram depicts vessel number per microscopic field that is increased in heparin-treated group, and is increased to a greater extent in the aFGF and aFGF/heparin groups, compared with saline solution controls. Error bars represent SEM. Journal of Vascular Surgery 1997 26, 302-312DOI: (10.1016/S0741-5214(97)70193-9) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 4 Vascular density (fibrofatty tissue). Biopsies of fibrofatty tissues distal to the point of vascular ligation were obtained 10 days after vascular occlusion in animals treated with daily administration of one of the following: 1 ml saline solution (n = 13); 0.05 mg heparin in 1 ml saline solution (n = 13); 1 μg aFGF (n = 5); or 1 μg recombinant human aFGF and 0.05 mg heparin in 1 ml saline solution (n = 5). Vessel number was determined per low power field (100×) as described in Methods section. Representative low power fields are depicted for (A) saline solution group and (B) aFGF/heparin-treated animals. C, Histogram depicts vessel number per microscopic field that is increased in heparin-treated group, and is increased to a greater extent in the aFGF and aFGF/heparin groups, compared with saline solution controls. Error bars represent SEM. Journal of Vascular Surgery 1997 26, 302-312DOI: (10.1016/S0741-5214(97)70193-9) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 5 Photomicrographs (original magnification, 400×) of fibrofatty tissue after various treatment regimens. Biopsies of fibrofatty tissues distal to the point of vascular ligation were obtained 10 days after vascular occlusion in animals treated with daily administration of one of the following: 1 ml saline solution (n = 13); 0.05 mg heparin in 1 ml saline solution (n = 13); 1 μg aFGF (n = 5); or 1 μg recombinant human aFGF and 0.05 mg heparin in 1 ml saline solution (n = 5), and prepared as described in Methods section. Vascular density compared with saline solution-treated controls (A) is increased in heparin-treated rats (B), and is increased to a greater extent in aFGF-treated animals (C) and aFGF/heparin-treated animals (D). Arrows depict vasculature. Journal of Vascular Surgery 1997 26, 302-312DOI: (10.1016/S0741-5214(97)70193-9) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 5 Photomicrographs (original magnification, 400×) of fibrofatty tissue after various treatment regimens. Biopsies of fibrofatty tissues distal to the point of vascular ligation were obtained 10 days after vascular occlusion in animals treated with daily administration of one of the following: 1 ml saline solution (n = 13); 0.05 mg heparin in 1 ml saline solution (n = 13); 1 μg aFGF (n = 5); or 1 μg recombinant human aFGF and 0.05 mg heparin in 1 ml saline solution (n = 5), and prepared as described in Methods section. Vascular density compared with saline solution-treated controls (A) is increased in heparin-treated rats (B), and is increased to a greater extent in aFGF-treated animals (C) and aFGF/heparin-treated animals (D). Arrows depict vasculature. Journal of Vascular Surgery 1997 26, 302-312DOI: (10.1016/S0741-5214(97)70193-9) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 5 Photomicrographs (original magnification, 400×) of fibrofatty tissue after various treatment regimens. Biopsies of fibrofatty tissues distal to the point of vascular ligation were obtained 10 days after vascular occlusion in animals treated with daily administration of one of the following: 1 ml saline solution (n = 13); 0.05 mg heparin in 1 ml saline solution (n = 13); 1 μg aFGF (n = 5); or 1 μg recombinant human aFGF and 0.05 mg heparin in 1 ml saline solution (n = 5), and prepared as described in Methods section. Vascular density compared with saline solution-treated controls (A) is increased in heparin-treated rats (B), and is increased to a greater extent in aFGF-treated animals (C) and aFGF/heparin-treated animals (D). Arrows depict vasculature. Journal of Vascular Surgery 1997 26, 302-312DOI: (10.1016/S0741-5214(97)70193-9) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 5 Photomicrographs (original magnification, 400×) of fibrofatty tissue after various treatment regimens. Biopsies of fibrofatty tissues distal to the point of vascular ligation were obtained 10 days after vascular occlusion in animals treated with daily administration of one of the following: 1 ml saline solution (n = 13); 0.05 mg heparin in 1 ml saline solution (n = 13); 1 μg aFGF (n = 5); or 1 μg recombinant human aFGF and 0.05 mg heparin in 1 ml saline solution (n = 5), and prepared as described in Methods section. Vascular density compared with saline solution-treated controls (A) is increased in heparin-treated rats (B), and is increased to a greater extent in aFGF-treated animals (C) and aFGF/heparin-treated animals (D). Arrows depict vasculature. Journal of Vascular Surgery 1997 26, 302-312DOI: (10.1016/S0741-5214(97)70193-9) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 6 Vascular density (skeletal muscle tissue). Biopsies of skeletal muscle tissue distal to the point of vascular ligation were obtained 10 days after vascular occlusion in the animals treated with daily administration of one of the following: 1 ml saline solution (n = 13); 0.05 mg heparin in 1 ml saline solution (n = 13); 1 μg aFGF (n = 5); or 1 μg recombinant human aFGF and 0.05 mg heparin in 1 ml saline solution (n = 5). Vessel number was determined per low power field (100×) as described in Methods section. Histogram depicts vessel number per microscopic field that is increased in the heparin-treated group, and is increased to a greater extent in aFGF and aFGF/heparin group, compared with saline solution controls. Error bars represent SEM. Journal of Vascular Surgery 1997 26, 302-312DOI: (10.1016/S0741-5214(97)70193-9) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions